Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL769571 | 0.86 | MCL1 (0.31) | MCL1 | |
| SCHEMBL1691636 | 0.78 | — | — | |
| SCHEMBL17494846 | 0.77 | — | — | |
| SCHEMBL1015369 | 0.76 | MCL1 (0.35) | MCL1 | |
| SCHEMBL31567182 | 0.75 | MCL1 (0.32) | MCL1 | |
| SCHEMBL3744331 | 0.75 | MGAM (0.31) | — | |
| SCHEMBL161037 | 0.74 | CYP2C9 (0.35) | — | |
| SCHEMBL2203061 | 0.74 | MAPT (0.31) | — | |
| SCHEMBL15007835 | 0.73 | MCL1 (0.33) | MCL1 | |
| Acetonitrile SCHEMBL25255519 | 0.73 | MCL1 (0.33) | MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108329246-B | Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as TRKA kinase inhibitors | 阵列生物制药公司 | 2021-02-26 | — | — | CN | disclosed |
| US-10889589-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | ARRAY BIOPHARMA INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-20190270749-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | ARRAY BIOPHARMA INC. (US) | 2019-09-05 | — | — | US | disclosed |
| US-10351575-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | ARRAY BIOPHARMA INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-10323022-B2 | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-20180334450-A1 | PYRROLIDINYL UREA, PYRROLIDINYL THIOUREA AND PYRROLIDINYL GUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2018-11-22 | — | — | US | disclosed |
| US-9981959-B2 | Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-9969694-B2 | N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9878997-B2 | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9822118-B2 | Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20130005751-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2013-01-03 | — | — | US | disclosed |
| WO-2012158413-A2 | PYRROLIDINYL UREA AND PYRROLIDINYL THIOUREA COMPOUNDS AS TRKA KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-11-22 | — | — | WO | disclosed |
| US-20120245187-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2012-09-27 | — | — | US | disclosed |
| US-20120245187-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2012-09-27 | — | — | US | disclosed |
| US-8242125-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2012-08-14 | — | — | US | disclosed |
| US-8242125-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2012-08-14 | — | — | US | disclosed |
| EP-2376478-A2 | PYRIDYLOXYINDOLES INHIBITORS OF VEGF-R2 AND USE THEREOF FOR TREATMENT OF DISEASE | Novartis AG (CH) | 2011-10-19 | — | — | EP | disclosed |
| US-20100168082-A1 | Heterobicyclic Carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2010-07-01 | — | — | US | disclosed |
| US-20100168082-A1 | Heterobicyclic Carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2010-07-01 | — | — | US | disclosed |
| WO-2010066684-A2 | Pyridyloxyindoles Inhibitors of VEGF-R2 and Use Thereof for Treatment of Disease | NOVARTIS AG (CH) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270749-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | TK1, UACA, TDP1 | MCL1 2540/4885 |
| US-10323022-B2 | Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors | RET, TK1, DSTYK | MCL1 2324/4885 |
| US-20120245187-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | CDK2, PHKG1, PHKG2 | MCL1 1222/4885 |
| US-20130005751-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | CDK2, PHKG1, PHKG2 | MCL1 1222/4885 |
| US-10889589-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | TK1, UACA, TDP1 | MCL1 2540/4885 |
| US-20180334450-A1 | PYRROLIDINYL UREA, PYRROLIDINYL THIOUREA AND PYRROLIDINYL GUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS | RET, TK1, DSTYK | MCL1 2324/4885 |
| US-20100168082-A1 | Heterobicyclic Carboxamides as inhibitors for kinases | CDK2, PHKG1, PHKG2 | MCL1 1222/4885 |
| US-10351575-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | TK1, UACA, TDP1 | MCL1 2540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.